Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | ATP6V1B2 | P21281 | 1/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
| ▸ | EDNRA | P25101 | 1/20 | 0.38 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.37 |
| ▸ | SUV39H2 | Q9H5I1 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2093718 | 1.00 | OPRK1 (0.40) | OPRK1KMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL10390924 | 0.90 | OPRK1 (0.40) | OPRK1KMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL2095446 | 0.85 | KMT2A (0.44) | OPRK1KMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL2093489 | 0.85 | MAP4K4 (0.43) | PDE10APIM1PIM3PIM2SUV39H2 | |
| SCHEMBL2093348 | 0.82 | SUV39H2 (0.40) | TRPV1PDE10ASUV39H2 | |
| SCHEMBL2093152 | 0.82 | SUV39H2 (0.40) | TRPV1PDE10ASUV39H2 | |
| SCHEMBL2093691 | 0.82 | LMNA (0.48) | KMT2AKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL2094400 | 0.81 | LMNA (0.42) | OPRK1KMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL9204536 | 0.81 | DPP4 (0.44) | KMT2AKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL9204530 | 0.81 | DPP4 (0.44) | KMT2AKDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163769-B2 | 1,8-naphthyridine derivatives | ABBOTT LABORATORIES (US) | 2012-04-24 | — | — | US | disclosed |
| US-20030232818-A1 | Antibacterial compounds | ABBVIE INC. | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232818-A1 | Antibacterial compounds | PGLS, UGT1A1, CASP1 | OPRK1 752/4885KMT2A 4682/4885KDM4E 4269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.